ATE326222T1 - Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch - Google Patents

Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch

Info

Publication number
ATE326222T1
ATE326222T1 AT01920377T AT01920377T ATE326222T1 AT E326222 T1 ATE326222 T1 AT E326222T1 AT 01920377 T AT01920377 T AT 01920377T AT 01920377 T AT01920377 T AT 01920377T AT E326222 T1 ATE326222 T1 AT E326222T1
Authority
AT
Austria
Prior art keywords
naltrexone
naloxone
treatment
analogs
pain
Prior art date
Application number
AT01920377T
Other languages
English (en)
Inventor
Wolfgang Sadee
Danxin Wang
Original Assignee
Wolfgang Sadee
Danxin Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22697044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE326222(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wolfgang Sadee, Danxin Wang filed Critical Wolfgang Sadee
Application granted granted Critical
Publication of ATE326222T1 publication Critical patent/ATE326222T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01920377T 2000-03-15 2001-03-15 Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch ATE326222T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18937200P 2000-03-15 2000-03-15

Publications (1)

Publication Number Publication Date
ATE326222T1 true ATE326222T1 (de) 2006-06-15

Family

ID=22697044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920377T ATE326222T1 (de) 2000-03-15 2001-03-15 Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch

Country Status (7)

Country Link
US (2) US20010049375A1 (de)
EP (1) EP1263438B1 (de)
AT (1) ATE326222T1 (de)
AU (1) AU4743601A (de)
CA (1) CA2403252A1 (de)
DE (1) DE60119696T2 (de)
WO (1) WO2001068080A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
DK1414451T3 (da) 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
SI1436012T1 (en) * 2001-10-18 2018-03-30 Nektar Therapeutics Polymer conjugates of opioid antagonists
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
EP1492505B1 (de) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmazeutische zubereitung enthaltend oxycodon und naloxon
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP2301537A1 (de) 2002-05-17 2011-03-30 Duke University Zonisamid zur Behandlung von Fettleibigkeit
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
MXPA05011557A (es) * 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
PL1694363T3 (pl) * 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
JP2007517901A (ja) * 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20070197573A1 (en) * 2005-10-04 2007-08-23 Wolfgang Sadee Compositions and methods in the treatment of bone metabolic disorders
CN1813740B (zh) * 2005-11-22 2010-05-05 岳振江 一种含有盐酸纳洛酮的舌下膜剂及其制备方法
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
KR101654176B1 (ko) 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX343867B (es) * 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2149047A4 (de) * 2007-04-30 2010-05-19 Univ Ohio State Res Found Polymorphismen in genen mit einfluss auf dopamintransporter-erkrankungen und ihre anwendungen
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
BRPI1006186A2 (pt) 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
EP2523557B1 (de) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Verfahren zur bereitstellung einer gewichtsverlusttherapie für patienten mit schweren depressionen
WO2011139525A1 (en) * 2010-05-05 2011-11-10 Philadelphia Health & Education Corporation Stereoisomer of naloxone and potential therapeutic action of opioid drugs to reverse clinical tolerance to these agents
US20130289060A1 (en) * 2010-10-19 2013-10-31 Memorial Sloan-Kettering Cancer Center 6-AMIDO DERIVATIVES OF 4, 5-a EPOXYMORPHINANS FOR THE TREATMENT OF PAIN
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
PL3148517T3 (pl) 2014-05-30 2021-11-29 The Research Foundation For The State University Of New York Kompozycje i sposoby do promowania tworzenia kości
EP3291676B1 (de) 2015-04-30 2022-08-17 Memorial Sloan Kettering Cancer Center Mitragynin-analoga und verwendungen davon
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
DK3400066T3 (da) 2016-01-08 2021-10-18 Ohio State Innovation Foundation Behandlinger og forebyggelse af neonatalt opioidt abstinenssyndrom
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20200101066A1 (en) 2017-03-28 2020-04-02 LDN Pharma Limited Agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US20220047580A1 (en) * 2019-01-04 2022-02-17 Aether Therapeutics Inc. Method for treating drug or alcohol dependency
WO2020178447A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method for determining efficacy
CN114364402A (zh) 2019-07-15 2022-04-15 罗瓦萨公司 用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂，特别是纳洛酮和/或纳曲酮
WO2022015364A1 (en) 2020-07-17 2022-01-20 Zetagen Therapeutics, Inc. Methods and compositions to graft bone using iron excipients
EP4366736A4 (de) * 2021-07-06 2025-05-14 Aether Therapeutics Inc. Niedrigdosiertes naltrexol und verwendungen davon
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer
US12403118B1 (en) 2025-03-05 2025-09-02 Zetagen Therapeutics, Inc. Cancer treatments using modified fatty acids and the carriers to administer them

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254088A (en) 1961-03-14 1966-05-31 Lewenstein Morphine derivative
NL280825A (de) 1962-07-11
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (de) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4816586A (en) 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5051426A (en) 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
CH683005A5 (it) * 1991-10-30 1993-12-31 Aldo Massarotti Procedimento per la preparazione, mediante ossidazione di N-ossidi per le terapie dei tossicomani da oppiati.
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5882944A (en) 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US6007986A (en) 1993-06-23 1999-12-28 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic activity screening
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
WO1996014071A1 (es) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combinacion de farmacos como medicamento destinado a supresion de dependencia de individuos a opiaceos
DE69630877T2 (de) 1995-03-31 2004-11-11 Xenova Research Ltd., Slough Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
EP0828489A4 (de) * 1996-03-13 2001-04-04 Univ Yale Raucherentwöhnungsbehandlung unter verwendung von naltrexon und verwandten verbindungen
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5760044A (en) * 1996-05-16 1998-06-02 Archer; Sydney Method for treating cocaine and amphetamine dependency
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
JP2002508753A (ja) * 1997-05-20 2002-03-19 エール ユニバーシティ オピエート拮抗薬及びセロトニン化合物を使用する薬物依存治療
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion

Also Published As

Publication number Publication date
WO2001068080A3 (en) 2002-07-04
US6713488B2 (en) 2004-03-30
US20010049375A1 (en) 2001-12-06
EP1263438A2 (de) 2002-12-11
DE60119696T2 (de) 2007-01-25
US20030069262A1 (en) 2003-04-10
WO2001068080A2 (en) 2001-09-20
DE60119696D1 (de) 2006-06-22
EP1263438B1 (de) 2006-05-17
CA2403252A1 (en) 2001-09-20
AU4743601A (en) 2001-09-24

Similar Documents

Publication Publication Date Title
ATE326222T1 (de) Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
WO2004017941A3 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
CA2302754A1 (en) Noribogaine in the treatment of pain and drug addiction
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
KR970009799A (ko) 물질 남용 금단의 치료 방법
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
WO2001091736A3 (en) Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
RU2001111868A (ru) Антагонисты метаботропных глутаматных рецепторов (mglur5) для лечения боли и состояния тревоги
Moriel et al. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction
NO20060913L (no) Behandling av avhengighetsabstinens
ES2253662T3 (es) Procedimiento de tratamiento de un paciente que requiere analgesia.
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
JP7244992B2 (ja) オピオイドとｎ－アシルエタノールアミンの組み合わせ
Komoda et al. Enhancement of lidocaine-induced epidural anesthesia by deoxyaconitine in the rabbit
WO2007059445A3 (en) Synergistic combinations of norketamine and opioid analgesics
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
US20040198723A1 (en) Method of treatment
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
MD1610F1 (en) Method of the recidivating chronic aphthous stomatitis treatment
Hanks Current Availability and Use of Morphine in Developed Countries and Relevance of Alternative Opioids to Morphine in Clinical Practice

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties